论文部分内容阅读
目的观察拉米夫定联合苦参素胶囊治疗慢性乙型肝炎的临床疗效。方法将97例慢性乙型肝炎患者随机分为治疗组(49例)和对照组(48例);治疗组给予口服拉米夫定和苦参素胶囊治疗,对照组仅口服拉米夫定,疗程6个月。结果治疗组总有效率为81.63%,对照组为68.75%(P<0.05)。治疗后两组丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)均降低(P<0.05),且治疗组的降低较对照组明显(P<0.05)。治疗组HBeAg和HBV-DNA阴转率分别为53.06%和65.31%,均高于对照组的41.67%和31.25%(P<0.05)。结论拉米夫定联合苦参素胶囊治疗慢性乙型肝炎疗效确切。
Objective To observe the clinical efficacy of lamivudine combined with kushenin capsule in the treatment of chronic hepatitis B. Methods Ninety-seven patients with chronic hepatitis B were randomly divided into treatment group (n = 49) and control group (n = 48). The treatment group was given orally lamivudine and oxymatrine capsules, while the control group was given lamivudine alone. Course of 6 months. Results The total effective rate was 81.63% in the treatment group and 68.75% in the control group (P <0.05). ALT and TBIL decreased after treatment in both groups (P <0.05), and the decrease in treatment group was more significant than that in control group (P <0.05). The negative rates of HBeAg and HBV-DNA in the treatment group were 53.06% and 65.31%, respectively, which were higher than those in the control group (41.67% and 31.25% respectively) (P <0.05). Conclusions lamivudine combined with oxymatrine capsule in the treatment of chronic hepatitis B is effective.